Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma.
Alessandro SteccoFrancesco BuemiAntoine IannessiAlessandro CarrieroAndrea GallaminiPublished in: Leukemia & lymphoma (2018)
Whole-body MRI (WB-MRI) with diffusion-weighted imaging (DWI) can now be used to stage and restage multiple myeloma (MM) and lymphoma. Magnetic resonance imaging (MRI) is the standard tool to detect BM involvement (BMI). The 2016 diagnostic criteria of the International Myeloma Working Group identify WB-MRI and fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) as the most sensitive imaging techniques for detecting skeletal and extra-skeletal MM invasion, respectively. Preliminary findings have also shown that WB-MRI is better than CT and equal to PET/CT in staging aggressive lymphoma and Hodgkin lymphoma, whereas MRI is better for diagnosing BMI in patients with low-grade lymphoma. Signal intensity (SI) and the apparent diffusion coefficient (ADC) are useful metrics to quantify the chemotherapy response in WB-MRI.
Keyphrases
- diffusion weighted imaging
- contrast enhanced
- magnetic resonance imaging
- computed tomography
- positron emission tomography
- diffusion weighted
- pet ct
- multiple myeloma
- low grade
- magnetic resonance
- diffuse large b cell lymphoma
- hodgkin lymphoma
- dual energy
- high resolution
- physical activity
- weight loss
- locally advanced
- weight gain
- pet imaging